The risk of immune-mediated liver injury from checkpoint inhibitors (ilici) in hcc is higher than in non-hcc cancers receiving the same regimenNiharika Mallepally,Elsie Ennin,Myra Ali,Layla Shojaie,Jeffrey A. Kahn,Kali Zhou,Jennifer L. Dodge,Lily DaraHEPATOLOGY(2022)引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要